145 related articles for article (PubMed ID: 11703321)
21. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.
Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Maertens J; Bormans G; Thomas J; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Blood; 2003 Jul; 102(1):53-9. PubMed ID: 12609836
[TBL] [Abstract][Full Text] [Related]
23. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
24. Clinical relevance of positron emission tomography (PET) in treatment control and relapse of Hodgkin's disease.
Lang O; Bihl H; Hültenschmidt B; Sautter-Bihl ML
Strahlenther Onkol; 2001 Mar; 177(3):138-44. PubMed ID: 11285771
[TBL] [Abstract][Full Text] [Related]
25. 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.
Rigacci L; Castagnoli A; Dini C; Carpaneto A; Matteini M; Alterini R; Carrai V; Nassi L; Bernardi F; Pieroni C; Bosi A
Oncol Rep; 2005 Nov; 14(5):1209-14. PubMed ID: 16211287
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
27. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
Cencini E; Fabbri A; Rigacci L; Lazzi S; Gini G; Cox MC; Mancuso S; Abruzzese E; Kovalchuk S; Goteri G; Di Napoli A; Bono R; Fratoni S; Di Lollo S; Bosi A; Leoncini L; Bocchia M
Hematol Oncol; 2017 Mar; 35(1):69-78. PubMed ID: 26251194
[TBL] [Abstract][Full Text] [Related]
30. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
[TBL] [Abstract][Full Text] [Related]
31. Advantages of positron emission tomography (PET) with respect to computed tomography in the follow-up of lymphoma patients with abdominal presentation.
Zinzani PL; Chierichetti F; Zompatori M; Tani M; Stefoni V; Garraffa G; Albertini P; Alinari L; Ferlin G; Baccarani M; Tura S
Leuk Lymphoma; 2002 Jun; 43(6):1239-43. PubMed ID: 12152991
[TBL] [Abstract][Full Text] [Related]
32. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
33. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.
Mikhaeel NG; Timothy AR; O'Doherty MJ; Hain S; Maisey MN
Leuk Lymphoma; 2000 Nov; 39(5-6):543-53. PubMed ID: 11342337
[TBL] [Abstract][Full Text] [Related]
34. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin's lymphoma in childhood and adolescence - consequences for the GPOH-HD 2003 protocol.
Körholz D; Kluge R; Wickmann L; Hirsch W; Lüders H; Lotz I; Dannenberg C; Hasenclever D; Dörffel W; Sabri O
Onkologie; 2003 Oct; 26(5):489-93. PubMed ID: 14605468
[TBL] [Abstract][Full Text] [Related]
35. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
Advani R; Maeda L; Lavori P; Quon A; Hoppe R; Breslin S; Rosenberg SA; Horning SJ
J Clin Oncol; 2007 Sep; 25(25):3902-7. PubMed ID: 17664458
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
[TBL] [Abstract][Full Text] [Related]
37. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.
Gallamini A; Hutchings M; Rigacci L; Specht L; Merli F; Hansen M; Patti C; Loft A; Di Raimondo F; D'Amore F; Biggi A; Vitolo U; Stelitano C; Sancetta R; Trentin L; Luminari S; Iannitto E; Viviani S; Pierri I; Levis A
J Clin Oncol; 2007 Aug; 25(24):3746-52. PubMed ID: 17646666
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease.
Wiedmann E; Baican B; Hertel A; Baum RP; Chow KU; Knupp B; Adams S; Hör G; Hoelzer D; Mitrou PS
Leuk Lymphoma; 1999 Aug; 34(5-6):545-51. PubMed ID: 10492078
[TBL] [Abstract][Full Text] [Related]
39. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
40. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker].
Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD
Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]